Nanobiotix Reports Promising Phase 2 Data for JNJ-1900 (NBTXR3) in Inoperable Lung Cancer
NBTX has more than doubled off its 52-week low of $2.986.
Summary
Nanobiotix announced promising initial Phase 2 clinical trial data for its nanoradioenhancer JNJ-1900 (NBTXR3) in stage 3 inoperable lung cancer, showing favorable safety and efficacy compared to benchmarks.
Key Events · Product Development and Regulatory · NBTX
-
Phase 2 Data Presented
First data from the randomized Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3) in Stage 3 inoperable non-small cell lung cancer was presented by Johnson & Johnson at the 2026 European Lung Cancer Conference.
-
Promising Efficacy Results
Initial efficacy responses in 7 patients showed an Overall Response Rate (ORR) of 71.4% and a Disease Control Rate (DCR) of 100%, which is promising relative to the estimated benchmark ORR of 45%-50%.
-
Favorable Safety Profile
The procedure demonstrated an acceptable safety profile without serious treatment-emergent adverse events (TEAEs) and did not adversely impact patients' ability to continue planned therapy.
Analysis · NBTX · Life Sciences
This filing reports positive initial data from a randomized Phase 2 trial for JNJ-1900 (NBTXR3) in a challenging indication, stage 3 inoperable non-small cell lung cancer. The acceptable safety profile and promising efficacy, with an Overall Response Rate (ORR) of 71.4% significantly exceeding the 45-50% benchmark, represent a material de-risking event for the program. The data, presented by partner Johnson & Johnson, reinforces the potential of this nanoradioenhancer and supports its broader development strategy, including the ongoing Phase 3 study in head and neck cancers.
At the time of this filing, NBTX was trading at $29.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $2.99 to $41.89. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.